Tuesday, May 30, 2023


Biotechnology News Magazine

Neuren Pharmaceuticals Receives Ethics Approval for Angelman Phase 2 Trial in Australia

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Neuren Pharmaceuticals (ASX: NEU) has received approval from the Human Research Ethics Committee for its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome (AS). The approval covers the three sites in Australia that will conduct the trial: Queensland Children’s Hospital/Centre for Children’s Health Research, South Brisbane, Sydney Children’s Hospital and Austin Health, Victoria. Separate research governance authorisation is now required from each site before they can be initiated and commence enrolment of subjects.

Neuren Pharmaceuticals CEO Jon Pilcher commented: “This is another important step achieved for the first clinical trial of NNZ-2591 in patients and Neuren’s first in Australia. We are very excited to be working closely with the local Angelman syndrome community and are eager to accelerate development of this potential therapy which has shown such promise to date.”

The AS Phase 2 trial will enroll up to 20 children aged 3 to 17 years to examine safety, tolerability, pharmacokinetics and efficacy over 13 weeks of treatment with orally administered NNZ-2591. Results from the trial are expected in H1 2023.

Neuren is also awaiting clearance from the US Food and Drug Administration (FDA) of Investigational New Drug (IND) applications for Phase 2 trials of NNZ-2591 in each of PhelanMcDermid syndrome and Pitt Hopkins syndrome. Both of those trials will be conducted in the United States.

In parallel with the Phase 2 trials, Neuren Pharmaceuticals is executing the foundational work to prepare for Phase 3 development of NNZ-2591 across these neurodevelopmental disorders and Prader-Willi syndrome, all of which have urgent need for an approved treatment.

About Angelman syndrome

There are currently no approved medicines for AS, which is characterized by severe developmental delay and learning disabilities that become noticeable by the age of 6 – 12 months. Children and adults with AS typically have balance issues, motor impairment and can have debilitating seizures. Some individuals never walk, most do not speak and disruptive sleep also can be a serious challenge. Individuals have a normal life expectancy, but they require continuous care and are unable to live independently. AS is caused by a loss of function of the UBE3A gene on chromosome 15.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine